DURECT Corporation Stock Price, News & Analysis (NASDAQ:DRRX)

$1.01 0.06 (6.32 %)
(As of 11/17/2017 06:49 AM ET)
Previous Close$0.95
Today's Range$0.94 - $1.03
52-Week Range$0.74 - $2.17
Volume689,699 shs
Average Volume703,627 shs
Market Capitalization$141.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

About DURECT Corporation (NASDAQ:DRRX)

DURECT Corporation logoDurect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:DRRX
  • CUSIP: N/A
  • Web: www.durect.com
Debt:
  • Debt-to-Equity Ratio: 1.46%
  • Current Ratio: 1.67%
  • Quick Ratio: 1.57%
Sales & Book Value:
  • Annual Sales: $14.02 million
  • Price / Sales: 10.70
  • Book Value: $0.07 per share
  • Price / Book: 14.43
Profitability:
  • Trailing EPS: ($0.15)
  • Net Income: ($34,500,000.00)
  • Net Margins: -62.57%
  • Return on Equity: -419.65%
  • Return on Assets: -45.77%
Misc:
  • Employees: 98
  • Outstanding Shares: 148,550,000
 

Frequently Asked Questions for DURECT Corporation (NASDAQ:DRRX)

What is DURECT Corporation's stock symbol?

DURECT Corporation trades on the NASDAQ under the ticker symbol "DRRX."

How were DURECT Corporation's earnings last quarter?

DURECT Corporation (NASDAQ:DRRX) issued its quarterly earnings results on Wednesday, November, 1st. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.09. The specialty pharmaceutical company had revenue of $20.75 million for the quarter, compared to analyst estimates of $5.09 million. DURECT Corporation had a negative return on equity of 419.65% and a negative net margin of 62.57%. View DURECT Corporation's Earnings History.

When will DURECT Corporation make its next earnings announcement?

DURECT Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for DURECT Corporation.

Where is DURECT Corporation's stock going? Where will DURECT Corporation's stock price be in 2017?

3 brokerages have issued twelve-month price targets for DURECT Corporation's stock. Their forecasts range from $2.00 to $3.00. On average, they expect DURECT Corporation's share price to reach $2.67 in the next twelve months. View Analyst Ratings for DURECT Corporation.

Are investors shorting DURECT Corporation?

DURECT Corporation saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,657,739 shares, an increase of 40.3% from the October 13th total of 1,181,204 shares. Based on an average trading volume of 1,709,988 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.2% of the shares of the stock are sold short.

Who are some of DURECT Corporation's key competitors?

Who are DURECT Corporation's key executives?

DURECT Corporation's management team includes the folowing people:

  • Felix D Theeuwes, Chairman, Chief Scientific Officer (Age 78)
  • James E. Brown DVM, President, Chief Executive Officer and Director (Age 58)
  • Matthew J. Hogan, Chief Financial Officer (Age 55)
  • Judy R. Joice, Senior Vice President - Operations and Corporate Quality Assurance (Age 58)
  • Myriam Theeuwes, Senior Vice President - Clinical Development
  • David R. Hoffmann, Lead Independent Director (Age 70)
  • Simon X. Benito, Independent Director (Age 72)
  • Terrence F. Blaschke M.D., Independent Director (Age 72)
  • Armand P. Neukermans Ph.D., Independent Director (Age 74)
  • Jon S. Saxe J.D., Independent Director (Age 80)

Who owns DURECT Corporation stock?

DURECT Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tocqueville Asset Management L.P. (1.39%), Mangrove Partners (0.86%), Asymmetry Capital Management L.P. (604,215.65%) and Schwab Charles Investment Management Inc. (0.18%). Company insiders that own DURECT Corporation stock include April Fund Lp 21, Armand Neukermans, Dave Hoffmann, Felix Theeuwes and James E Brown. View Institutional Ownership Trends for DURECT Corporation.

Who sold DURECT Corporation stock? Who is selling DURECT Corporation stock?

DURECT Corporation's stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P.. View Insider Buying and Selling for DURECT Corporation.

Who bought DURECT Corporation stock? Who is buying DURECT Corporation stock?

DURECT Corporation's stock was bought by a variety of institutional investors in the last quarter, including Mangrove Partners, Tocqueville Asset Management L.P. and Schwab Charles Investment Management Inc.. Company insiders that have bought DURECT Corporation stock in the last two years include April Fund Lp 21, Armand Neukermans, Dave Hoffmann, Felix Theeuwes and James E Brown. View Insider Buying and Selling for DURECT Corporation.

How do I buy DURECT Corporation stock?

Shares of DURECT Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DURECT Corporation's stock price today?

One share of DURECT Corporation stock can currently be purchased for approximately $1.01.

How big of a company is DURECT Corporation?

DURECT Corporation has a market capitalization of $141.92 million and generates $14.02 million in revenue each year. The specialty pharmaceutical company earns ($34,500,000.00) in net income (profit) each year or ($0.15) on an earnings per share basis. DURECT Corporation employs 98 workers across the globe.

How can I contact DURECT Corporation?

DURECT Corporation's mailing address is 10260 Bubb Rd, CUPERTINO, CA 95014-4166, United States. The specialty pharmaceutical company can be reached via phone at +1-408-7771417.


MarketBeat Community Rating for DURECT Corporation (NASDAQ DRRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  186
MarketBeat's community ratings are surveys of what our community members think about DURECT Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for DURECT Corporation (NASDAQ:DRRX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $2.67 (164.03% upside)

Consensus Price Target History for DURECT Corporation (NASDAQ:DRRX)

Price Target History for DURECT Corporation (NASDAQ:DRRX)

Analysts' Ratings History for DURECT Corporation (NASDAQ:DRRX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/2/2017HC WainwrightReiterated RatingHoldN/AView Rating Details
10/20/2017LaidlawLower Price TargetBuy -> Buy$3.00 -> $2.00N/AView Rating Details
10/20/2017Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
9/27/2016Rodman & RenshawReiterated RatingBuy$4.00 -> $3.50N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for DURECT Corporation (NASDAQ:DRRX)

Earnings by Quarter for DURECT Corporation (NASDAQ:DRRX)

Earnings History by Quarter for DURECT Corporation (NASDAQ DRRX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018        
11/1/2017Q3 2017($0.05)$0.04$5.09 million$20.75 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.05)($0.07)$5.17 million$4.32 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)$3.60 million$4.57 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.06)($0.06)$3.03 million$3.52 millionViewN/AView Earnings Details
10/31/2016Q316($0.07)($0.06)$3.72 million$37.00 millionViewListenView Earnings Details
8/1/2016Q216($0.06)($0.07)$3.69 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.06)$4.09 million$3.60 millionViewListenView Earnings Details
2/29/2016Q415($0.06)($0.05)$4.83 million$5.20 millionViewListenView Earnings Details
11/2/2015Q315($0.05)($0.05)$5.08 million$4.70 millionViewListenView Earnings Details
8/3/2015Q215($0.06)($0.05)$5.01 million$4.40 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.04)$4.82 million$4.77 millionViewListenView Earnings Details
3/2/2015Q414($0.05)($0.05)$4.32 million$4.30 millionViewListenView Earnings Details
11/3/2014Q3($0.05)($0.06)$4.10 million$4.26 millionViewListenView Earnings Details
8/7/2014Q2($0.05)($0.05)$3.90 million$4.58 millionViewListenView Earnings Details
5/1/2014Q1($0.05)($0.03)$4.12 million$6.30 millionViewListenView Earnings Details
2/27/2014Q4($0.06)($0.05)$2.79 million$4.30 millionViewListenView Earnings Details
8/5/2013Q2 2013($0.05)($0.05)$3.42 million$3.92 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for DURECT Corporation (NASDAQ:DRRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.03)($0.03)($0.03)
Q3 20171($0.01)($0.01)($0.01)
Q4 20171($0.02)($0.02)($0.02)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for DURECT Corporation (NASDAQ:DRRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for DURECT Corporation (NASDAQ DRRX)

Insider Ownership Percentage: 10.30%
Institutional Ownership Percentage: 46.00%
Insider Trades by Quarter for DURECT Corporation (NASDAQ:DRRX)
Institutional Ownership by Quarter for DURECT Corporation (NASDAQ:DRRX)

Insider Trades by Quarter for DURECT Corporation (NASDAQ DRRX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/3/2016April Fund L.P. 21Major ShareholderBuy95,000$1.16$110,200.00View SEC Filing  
9/26/2016April Fund L.P. 21Major ShareholderBuy2,500,000$1.15$2,875,000.00View SEC Filing  
4/26/2016April Fund L.P. 21Major ShareholderBuy5,500,000$1.25$6,875,000.00View SEC Filing  
4/26/2016Dave HoffmannDirectorBuy200,000$1.25$250,000.00View SEC Filing  
4/26/2016Felix TheeuwesChairmanBuy160,000$1.25$200,000.00View SEC Filing  
3/14/2016Armand NeukermansDirectorBuy18,000$1.39$25,020.00View SEC Filing  
3/14/2016Felix TheeuwesChairmanBuy70,000$1.41$98,700.00View SEC Filing  
3/10/2016James E BrownCEOBuy20,000$1.33$26,600.00View SEC Filing  
1/11/2016April Fund Lp 21Major ShareholderBuy300,100$1.37$411,137.00View SEC Filing  
9/29/2015April Fund Ltd 21Major ShareholderBuy952,249$1.79$1,704,525.71View SEC Filing  
3/10/2015Simon X BenitoDirectorBuy40,000$1.81$72,400.00View SEC Filing  
3/9/2015Felix TheeuwesChairmanBuy225,600$1.65$372,240.00View SEC Filing  
3/6/2015Felix TheeuwesChairmanBuy380,000$1.57$596,600.00View SEC Filing  
11/21/2014Felix TheeuwesChairmanBuy72,700$1.00$72,700.00View SEC Filing  
11/20/2014Felix TheeuwesChairmanBuy136,015$0.92$125,133.80View SEC Filing  
11/8/2013Felix TheeuwesChairmanBuy714,285$1.40$999,999.00View SEC Filing  
9/10/2013Felix TheeuwesChairmanBuy75,000$1.20$90,000.00View SEC Filing  
9/9/2013Felix TheeuwesChairmanBuy25,000$1.15$28,750.00View SEC Filing  
6/4/2013James E BrownCEOBuy30,000$0.80$24,000.00View SEC Filing  
12/12/2012Jon S SaxeDirectorBuy15,000$0.91$13,650.00View SEC Filing  
11/14/2012Felix TheeuwesChairmanBuy100,000$1.01$101,000.00View SEC Filing  
8/28/2012Jon S SaxeDirectorBuy7,810$0.97$7,575.70View SEC Filing  
8/23/2012Jon S SaxeDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for DURECT Corporation (NASDAQ:DRRX)

Latest Headlines for DURECT Corporation (NASDAQ DRRX)

Source:
DateHeadline
The Stock Market Cycle And Implications For Medical Stock InvestingThe Stock Market Cycle And Implications For Medical Stock Investing
seekingalpha.com - November 14 at 6:27 PM
Financial Survey: MacroGenics (MGNX) and DURECT Corporation (DRRX)Financial Survey: MacroGenics (MGNX) and DURECT Corporation (DRRX)
www.americanbankingnews.com - November 13 at 3:59 PM
DURECT Corporation (DRRX) Sees Large Increase in Short InterestDURECT Corporation (DRRX) Sees Large Increase in Short Interest
www.americanbankingnews.com - November 13 at 3:34 AM
DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 10:46 AM
DURECT Corporation (DRRX) to Post FY2017 Earnings of ($0.13) Per Share, Zacks Investment Research ForecastsDURECT Corporation (DRRX) to Post FY2017 Earnings of ($0.13) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - November 6 at 6:14 AM
$4.72 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter$4.72 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter
www.americanbankingnews.com - November 3 at 6:08 AM
DRRX: Focus will be Shifted to DUR-928 ProgramsDRRX: Focus will be Shifted to DUR-928 Programs
finance.yahoo.com - November 2 at 7:04 PM
DURECT Corp (DRRX) Tops Q3 EPS by 10c - StreetInsider.comDURECT Corp (DRRX) Tops Q3 EPS by 10c - StreetInsider.com
www.streetinsider.com - November 2 at 5:07 AM
Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 5:07 AM
DURECTs (DRRX) CEO James Brown on Q3 2017 Results - Earnings Call TranscriptDURECT's (DRRX) CEO James Brown on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 12:04 AM
DURECT Corporation (DRRX) Announces Quarterly  Earnings Results, Beats Estimates By $0.10 EPSDURECT Corporation (DRRX) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - November 1 at 8:34 PM
DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate UpdateDURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 1 at 7:01 PM
Durect tops Street 3Q forecastsDurect tops Street 3Q forecasts
finance.yahoo.com - November 1 at 7:01 PM
FY2018 EPS Estimates for DURECT Corporation Reduced by Analyst (DRRX)FY2018 EPS Estimates for DURECT Corporation Reduced by Analyst (DRRX)
www.americanbankingnews.com - October 27 at 5:48 PM
DURECT Corporation Invites You to Join its Third Quarter 2017 ... - PR Newswire (press release)DURECT Corporation Invites You to Join its Third Quarter 2017 ... - PR Newswire (press release)
www.prnewswire.com - October 26 at 11:57 PM
DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference CallDURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call
finance.yahoo.com - October 26 at 6:54 PM
ETFs with exposure to DURECT Corp. : October 26, 2017ETFs with exposure to DURECT Corp. : October 26, 2017
finance.yahoo.com - October 26 at 1:51 PM
Durect Takes A Beating On Pain Drug, Still holds Enormous Potential Value - Seeking AlphaDurect Takes A Beating On Pain Drug, Still holds Enormous Potential Value - Seeking Alpha
seekingalpha.com - October 23 at 6:29 PM
DURECT Co. (DRRX) to Release Quarterly Earnings on MondayDURECT Co. (DRRX) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 10:56 AM
UPDATE: H.C. Wainwright Downgrades Durect Corp (DRRX) to NeutralUPDATE: H.C. Wainwright Downgrades Durect Corp (DRRX) to Neutral
www.streetinsider.com - October 21 at 5:20 PM
DURECT Corporation (DRRX) Cut to Hold at Stifel NicolausDURECT Corporation (DRRX) Cut to Hold at Stifel Nicolaus
www.americanbankingnews.com - October 21 at 3:34 PM
HC Wainwright Lowers DURECT Corporation (DRRX) to NeutralHC Wainwright Lowers DURECT Corporation (DRRX) to Neutral
www.americanbankingnews.com - October 21 at 2:58 PM
DURECT Corporation (DRRX) Cut to "Strong Sell" at ValuEngineDURECT Corporation (DRRX) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - October 21 at 10:40 AM
Mid-Day Market Update: Dow Surges Over 100 Points; DURECT ... - NasdaqMid-Day Market Update: Dow Surges Over 100 Points; DURECT ... - Nasdaq
www.nasdaq.com - October 21 at 5:36 AM
DURECTs pain med Posimir flunks late-stage study; shares plummet 55% premarket - Seeking AlphaDURECT's pain med Posimir flunks late-stage study; shares plummet 55% premarket - Seeking Alpha
seekingalpha.com - October 21 at 5:36 AM
UPDATE: Durect Corp (DRRX) PT Lowered to $2 at Laidlaw - StreetInsider.comUPDATE: Durect Corp (DRRX) PT Lowered to $2 at Laidlaw - StreetInsider.com
www.streetinsider.com - October 21 at 5:36 AM
Pre-Open Stock Movers 10/20: (SKX) (TEAM) (QURE) Higher; (DRRX) (NCR) (CELG) (GE) Lower (more...)Pre-Open Stock Movers 10/20: (SKX) (TEAM) (QURE) Higher; (DRRX) (NCR) (CELG) (GE) Lower (more...)
www.streetinsider.com - October 20 at 7:31 PM
DURECT Corporation (DRRX) Shares Collapse – Here’s WhyDURECT Corporation (DRRX) Shares Collapse – Here’s Why
finance.yahoo.com - October 20 at 7:31 PM
Laidlaw Trims DURECT Corporation (DRRX) Target Price to $2.00Laidlaw Trims DURECT Corporation (DRRX) Target Price to $2.00
www.americanbankingnews.com - October 20 at 10:12 AM
DURECT Corp (DRRX) PERSIST Phase 3 Trial of POSIMIR Misses ... - StreetInsider.comDURECT Corp (DRRX) PERSIST Phase 3 Trial of POSIMIR Misses ... - StreetInsider.com
www.streetinsider.com - October 19 at 11:38 PM
DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy EndpointDURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
finance.yahoo.com - October 19 at 6:36 PM
ETFs with exposure to DURECT Corp. : October 16, 2017ETFs with exposure to DURECT Corp. : October 16, 2017
finance.yahoo.com - October 16 at 6:41 PM
Zacks: Brokerages Anticipate DURECT Corporation (DRRX) Will Announce Quarterly Sales of $5.09 MillionZacks: Brokerages Anticipate DURECT Corporation (DRRX) Will Announce Quarterly Sales of $5.09 Million
www.americanbankingnews.com - October 15 at 8:06 AM
DURECT Corporation (DRRX) Expected to Announce Earnings of -$0.05 Per ShareDURECT Corporation (DRRX) Expected to Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - October 13 at 12:12 PM
$5.09 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter$5.09 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter
www.americanbankingnews.com - October 12 at 10:54 AM
Zacks: Brokerages Expect DURECT Corporation (DRRX) Will Post Earnings of -$0.05 Per ShareZacks: Brokerages Expect DURECT Corporation (DRRX) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - October 10 at 8:20 PM
Comparing DURECT Corporation (DRRX) & Atara Biotherapeutics (ATRA)Comparing DURECT Corporation (DRRX) & Atara Biotherapeutics (ATRA)
www.americanbankingnews.com - October 8 at 10:38 AM
ETFs with exposure to DURECT Corp. : October 5, 2017ETFs with exposure to DURECT Corp. : October 5, 2017
finance.yahoo.com - October 5 at 5:12 PM
Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting SchizophreniaStreetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia
finance.yahoo.com - October 5 at 10:08 AM
DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 10:55 AM
DURECT Corp (DRRX) Announces $12.5M Patent Purchase Agreement with Indivior UK Limited - StreetInsider.comDURECT Corp (DRRX) Announces $12.5M Patent Purchase Agreement with Indivior UK Limited - StreetInsider.com
www.streetinsider.com - October 3 at 5:55 PM
DURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLCDURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLC
finance.yahoo.com - October 3 at 5:55 PM
Short Interest in DURECT Corporation (DRRX) Drops By 23.5%Short Interest in DURECT Corporation (DRRX) Drops By 23.5%
www.americanbankingnews.com - October 1 at 1:18 AM
DURECT Corporation (DRRX) & MannKind Corporation (MNKD) Critical ReviewDURECT Corporation (DRRX) & MannKind Corporation (MNKD) Critical Review
www.americanbankingnews.com - September 22 at 4:26 PM
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical DevelopmentDURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
finance.yahoo.com - September 20 at 6:53 PM
Head to Head Review: DURECT Corporation (DRRX) vs. Its PeersHead to Head Review: DURECT Corporation (DRRX) vs. Its Peers
www.americanbankingnews.com - September 16 at 10:32 AM
Durect (DRRX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowDurect (DRRX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 7:20 PM
2017: The Biopharma Summer Of Love2017: The Biopharma Summer Of Love
seekingalpha.com - September 8 at 6:26 PM
DURECT to Participate in Upcoming Healthcare ConferencesDURECT to Participate in Upcoming Healthcare Conferences
finance.yahoo.com - September 5 at 7:34 PM
DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United StatesDRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States
finance.yahoo.com - August 10 at 7:16 PM

Social Media

Financials

Chart

DURECT Corporation (NASDAQ DRRX) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.